



SANDU PHARMACEUTICALS LTD

Regd. Office: Plot Nos. 25, 26, 29 & 30, Pilerne Industrial Estate, Marra, Saligao, Bardez, Goa 403511.
Tel: +91 832 2407474 / 6715000, E-mail: sandupharma@sandu.in

Ref: SPL/CORP-SEC/2021-22/BSE/72

Dated: 14.08.2021

To,

Bombay Stock Exchange Ltd,
Phirojshah Jeejobhoy Towers,
25th Floor, Dalal Street,
Mumbai 400 001

Manager-Department of Corporate affairs

Sir,

Sub: Outcome of the Board Meeting with Scrip Code 524703.

A Meeting of the Board of Directors of the Company duly convened on Saturday, 14th August 2021 **at 05:00 p.m. and concluded at 06:05 p.m.** discussed the following business: -

1. Considered, Approved and took on record Unaudited Financial Results for the Quarter 30th June 2021.
2. Approved Directors Report, Management Discussion and Analysis Report, Corporate Governance Report, Secretarial Audit Report etc for the year ended 31st March 2021.
3. Recommended Dividend of Rs 0.50 paise/- per Equity Shares(i.e 5% on paid up Share Capital of the Company) having face value of Rs 10/- each for the Financial Year ended 31st March 2021, upon approval of the final dividend by the Shareholders at the 36th Annual General Meeting, the dividend amount after deducting applicable TDS, will be credited to the Bank Accounts of the Shareholders who have registered their Bank Account details with the Depository/ Company and for those Shareholders who have not registered their Bank Account details, dividend warrants will be dispatched on or before 20th October 2021.
4. To close Register of Members and Share Transfer Books of the Company from Friday, 24th September 2021 to Thursday, 30th September 2021 both days inclusive.
5. To convene the 36th Annual General Meeting of the Company on Thursday, the 30th September 2021 in video conferencing/other Audio Visual Means, details on the manner of attending the AGM and casting votes by Shareholders will be set out in the Notice of the AGM.
6. Took note of Statement of Utilizations and Deviations as per Regulation 32 of SEBI (LODR) Regulation 2015 for the Quarter ended 30th June 2021.

You are requested to kindly take the same on record.

Yours Faithfully,



AN ISO 9001:2008 CERTIFIED ORGANISATION

Corporate Office: P. B. No. 17201, Sandu Nagar, D. K. Sandu Marg, Chembur, Mumbai – 400 071.
Tel.: +91 22 2528 4402 / 3306, Fax: +91 22 2528 2403, E-mail: info@sandu.in, Web: www.sandu.in

CIN:L24233GA1985PLC001587





SANDU PHARMACEUTICALS LTD

Regd. Office: Plot Nos. 25, 26, 29 & 30, Pilerne Industrial Estate, Marra, Saligao, Bardez, Goa 403511.
Tel: +91 832 2407474 / 6715000, E-mail: sandupharma@sandu.in

For Sandu Pharmaceuticals Limited



Company Secretary



AN ISO 9001:2008 CERTIFIED ORGANISATION

Corporate Office: P. B. No. 17201, Sandu Nagar, D. K. Sandu Marg, Chembur, Mumbai – 400 071.
Tel.: +91 22 2528 4402 / 3306, Fax: +91 22 2528 2403, E-mail: info@sandu.in, Web: www.sandu.in

CIN: L24233GA1985PLC001587



Sandu Pharmaceuticals Ltd				
STATEMENT OF UNAUDITED RESULTS FOR THE PERIOD ENDED 30/06/21				
(Rs in Lakhs)				
Particulars	Qtr Ending June 2021 (Un audited)	Qtr Ending March 2021 (Audited)	Qtr Ending June 2020 (Un Audited)	Year Ended March 2021 (Audited)
I Revenue From Operations	1,733.59	1,409.54	1,166.97	5,875.54
II Other Income	2.34	3.07	2.38	19.34
III Total Income (I+II)	1,735.93	1,412.61	1,169.35	5,894.88
IV EXPENSES				
Cost of materials consumed	259.65	365.45	192.01	1,187.18
Purchases of Stock-in-Trade	676.95	641.34	211.83	1,924.13
Changes in inventories of finished goods, Stock-in -Trade and work-in-progress	148.04	(315.85)	369.06	338.70
Employee benefits expense	216.84	143.89	148.40	801.82
Finance costs	3.83	5.77	7.15	11.49
Depreciation and amortization expense	13.19	13.81	13.74	55.67
Other expenses	358.97	492.51	221.21	1,407.80
Total expenses (IV)	1,677.47	1,346.92	1,163.39	5,726.79
V Profit/(loss) before exceptional items and tax (I- IV)	58.46	65.69	5.96	168.09
VI Exceptional Items			-	-
VII Profit/(loss) before tax (V-VI)	58.46	65.69	5.96	168.09
VIII Tax expense:				
(1) Current tax	16.27	17.08	2.00	55.71
(2) Deferred tax	0.37	2.30	0.16	2.95
Short / (Excess) Tax Provision		0.18		0.18
IX Profit (Loss) for the period from continuing operations (VII-VIII)	41.82	46.13	3.80	109.25
X Profit/(loss) for the period (IX+XII)	41.82	46.13	3.80	109.25
XI Other Comprehensive Income				
A (i) Items that will not be reclassified to profit or loss				
a. Remeasurement gains/(losses) on post employment defined benefit plans		1.90		1.90
b. Fair value changes of investments	5.98	12.01	14.68	58.30
(ii) Income tax relating to items that will not be reclassified to profit or loss	(0.66)	(2.98)	(1.52)	(7.79)
B (i) Items that will be reclassified to profit or loss				
(ii) Income tax relating to items that will be reclassified to profit or loss				
Total Comprehensive Income for the period (XIII+XIV)(Comprising Profit (Loss) and Other Comprehensive Income for the period)	47.14	57.06	16.96	161.66
XIV Paid Up Equity Capital (Face Value of Rs 10/- Per share)	792.09	792.09	708.10	792.09
XVI Earnings per equity share (for continuing operation):				
(1) Basic	0.53	0.65	0.05	1.54
(2) Diluted	0.48	0.65	0.05	1.54

Place :- Mumbai
Date :- 14/08/2021

For Sandu Pharmaceuticals Ltd


Umesh Sandu
Managing Director
DIN :- 01132141



1. The above results published in accordance with regulation 33 of the SEBI (Listing Obligation & Disclosures Requirements), 2015 have been reviewed by the Audit committee and approved by the Board of Directors at their meeting held on 14th August , 2021. The Financials results are in accordance with the Indian Accounting Standards (IND AS) as prescribed under Section 133 of the Companies Act, 2013 read with Rule 3 of the Companies (Indian Accounting Standards) Rule, 2015 and Companies (Indian Accounting Standards) Amendment Rules, 2017.
2. The Management evaluates the performance of the company based on revenue and operating income in one segment i.e. "Ayurvedic Medicines". Accordingly, as per IND AS- 108. The company has only one business segment and hence segment information has not been separately disclosed.
3. The Company has considered the possible impact of COVID 19 pandemic on its operations, liquidity position and recoverability of its assets balances at 30th June ,2021 based on the internal and external information up to the date of approval of these financial results .The impact of COVID 19 may be different from that estimated as at the time of approval of these financial results and management will continue to monitor any material changes arising due to the impact of this pandemic on financial and operational performance of the company and take necessary measures to address the situation.
4. The Figures for the quarter ended 31 st March, 2021 are the balancing figures between the audited figures in respect of the full financial year and the published year to date figures up to the third quarter of the respective financial year.
5. Figures for the previous periods have been reclassified/regrouped, whenever necessary.
6. The Above results are reviewed and recommended by the audit committee and approved by Board of Directors at the meeting held on 14th August ,2021 and there are no qualification in the audit report for the quarter ended , 30th June , 2021.

Date: - 14/08/2021

For Sandu Pharmaceuticals Ltd


Umesh Sandu

Managing Director

DIN :- 01132141





"LIMITED REVIEW" REPORT ON THE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER
ENDED ON 30th JUNE, 2021


To,

The Board of Directors,
Sandu Pharmaceuticals Limited,
Plot No. 25, 26, 29 & 30,
Pilerne Industrial Estate, Marra,
Bardez, Goa-403511.

Dear Sirs,

1. We have reviewed the accompanying Statement of Unaudited Financial Results of **Sandu Pharmaceuticals Limited** ("the Company") for the quarter ended on 30th June, 2021, prepared by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
2. This Statement is the responsibility of the Company's Management and has been approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" (Ind As 34), prescribed under section 133 of the Companies Act, 2013 read with the relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on these standalone financial statements based on our review.
3. We conducted our review in accordance with the Standard on Review Engagement (*SRE*) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of Unaudited Financial Results prepared in accordance with the applicable Indian Accounting Standards prescribed under Section 133 of the Companies Act, 2013, read with relevant rules issued there under and other recognised accounting practices and principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Dileep & Prithvi
Chartered Accountants
Firm Registration Number: 122290W


Himmat Mali

(Partner)

Membership Number: 183378
UDIN- 21183378AAAACI9011



Place: Mumbai
Date: 14th August, 2021